论文部分内容阅读
系前瞻性研究，观察盐酸噻氯匹啶抗血小板聚集作用。149例用药前血小板聚集功能≥50％者入选，其中55例随机分组与肠溶阿斯匹林对照。试验组（T组）眼盐酸噻氯匹啶250mg／日，对照组（C组）服肠溶阿斯匹林75mg／日，均为4周。眼药后2周末、4周末测定血小板聚集功能（ADP诱导，0．2μmol／L）证实盐酸噻氯匹啶抗血小板聚集功能确切，显效率61．1％，总有效率96．8％。肠溶阿斯匹林亦能降低血小板聚集功能，显效率14．8％，总有效率61．1％。盐酸噻氯匹啶不良反应与肠溶阿斯匹林相近，不良反应发生率10．5％。
Department of Prospective study to observe the anti-platelet aggregation of ticlopidine hydrochloride. 149 cases of pre-treatment platelet aggregation function ≥ 50% were selected, of which 55 cases were randomized and enteric-coated aspirin control. The test group (T group) eye ticlopidine hydrochloride 250mg / day, the control group (C group) enteric coated aspirin 75mg / day, were 4 weeks. After 2 days and 4 weeks after ophthalmic treatment, platelet aggregation (ADP-induced, 0.2μmol / L) confirmed that ticlopidine hydrochloride had an effective anti-platelet aggregation function with a markedly effective rate of 61.1% and a total effective rate of 96.8%. Enteric aspirin can also reduce platelet aggregation function, markedly effective rate of 14.8%, the total effective rate of 61.1%. Adverse reactions of ticlopidine hydrochloride and enteric-coated aspirin similar, the incidence of adverse reactions 10.5%.